Cargando…

A Novel Polyamine-Targeted Therapy for BRAF Mutant Melanoma Tumors

Mutant serine/threonine protein kinase B-Raf (BRAF) protein is expressed in over half of all melanoma tumors. Although BRAF inhibitors (BRAFi) elicit rapid anti-tumor responses in the majority of patients with mutant BRAF melanoma, the tumors inevitably relapse after a short time. We hypothesized th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peters, Molly C., Minton, Allyson, Phanstiel, Otto, Gilmour, Susan K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872160/ https://www.ncbi.nlm.nih.gov/pubmed/29304009 http://dx.doi.org/10.3390/medsci6010003

Ejemplares similares

A novel polyamine blockade therapy activates an anti-tumor immune response
por: Alexander, Eric T., et al.
Publicado: (2017)

Loss of Anti-Tumor Efficacy by Polyamine Blocking Therapy in GCN2 Null Mice
por: Alexander, Eric T., et al.
Publicado: (2023)

Polyamine-Based Nanostructures Share Polyamine Transport Mechanisms with Native Polyamines and Their Analogues: Significance for Polyamine-Targeted Therapy
por: Holbert, Cassandra E., et al.
Publicado: (2022)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

Investigation of Polyamine Metabolism and Homeostasis in Pancreatic Cancers
por: Massaro, Chelsea, et al.
Publicado: (2017)

Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment
por: Alexander, Eric T., et al.
Publicado: (2016)

Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches
por: Khaddour, Karam, et al.
Publicado: (2021)

Differential Expression of Polyamine Pathways in Human Pancreatic Tumor Progression and Effects of Polyamine Blockade on Tumor Microenvironment
por: Nakkina, Sai Preethi, et al.
Publicado: (2021)

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
por: Warburton, L., et al.
Publicado: (2020)

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
por: Trojaniello, Claudia, et al.
Publicado: (2023)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
por: Dar, Nakul, et al.
Publicado: (2023)

ATP13A3 facilitates polyamine transport in human pancreatic cancer cells
por: Sekhar, Vandana, et al.
Publicado: (2022)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

Evaluation of Polyamine Transport Inhibitors in a Drosophila Epithelial Model Suggests the Existence of Multiple Transport Systems
por: Wang, Minpei, et al.
Publicado: (2017)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Variations of BRAF mutant allele percentage in melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2015)

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Rebalancing polyamine levels to treat Snyder–Robinson syndrome
por: Gilmour, Susan K
Publicado: (2023)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Identification of Trypanosoma cruzi Polyamine Transport Inhibitors by Computational Drug Repurposing
por: Reigada, Chantal, et al.
Publicado: (2019)

Elucidating the Role of Chmp1 Overexpression in the Transport of Polyamines in Drosophila melanogaster
por: Stump, Coryn L., et al.
Publicado: (2022)

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
por: Smit, Marjon A, et al.
Publicado: (2014)

Polyamine blockade promotes antitumor immunity
por: Hayes, Candace S, et al.
Publicado: (2014)

Molecular targeted therapy of BRAF-mutant colorectal cancer
por: Ducreux, Michel, et al.
Publicado: (2019)

Uptake of Biotinylated Spermine in Astrocytes: Effect of Cx43 siRNA, HIV-Tat Protein and Polyamine Transport Inhibitor on Polyamine Uptake
por: Malpica-Nieves, Christian J., et al.
Publicado: (2021)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

Genetic portrait of polyamine transporters in barley: insights in the regulation of leaf senescence
por: Stolarska, Ewelina, et al.
Publicado: (2023)

AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis
por: McRee, Siobhan K., et al.
Publicado: (2023)

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
por: Carlino, Matteo S, et al.
Publicado: (2016)

Targeting BRAF for patients with melanoma
por: Arkenau, H-T, et al.
Publicado: (2011)

Efficacy of Targeted Radionuclide Therapy Using [(131)I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma
por: Akil, Hussein, et al.
Publicado: (2021)

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
por: Mak, Gabriel, et al.
Publicado: (2014)

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
por: Kim, Jae-Hyeon, et al.
Publicado: (2017)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
por: Vanni, Irene, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lcuam80915vnq98avi3o79b12m